Craig-Hallum initiated coverage of Atossa Therapeutics (ATOS) with a Buy rating and $4 price target
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATOS:
- Atossa Therapeutics Reports Q1 2025 Financial Results
- Atossa Therapeutics: Strategic Advancements and Promising Clinical Developments Drive Buy Rating
- Atossa Therapeutics reports results from Phase 2 EOP sub-study
- Optimistic Buy Rating for Atossa Therapeutics Driven by Strategic Focus on Z-endoxifen and Strong Financial Position
- Biotech Alert: Searches spiking for these stocks today